Technical Analysis for AVCT - Avacta Group Plc

Grade Last Price % Change Price Change
F 49.75 1.53% 0.75
AVCT closed up 1.53 percent on Thursday, March 28, 2024, on 1.24 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
6 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Low Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 1.53%
New 52 Week Low Weakness 1.53%
Multiple of Ten Bearish Other 1.53%
Lower Bollinger Band Touch Weakness 1.53%
Oversold Stochastic Weakness 1.53%
Wide Bands Range Expansion -2.26%
Oversold Stochastic Weakness -2.26%

   Recent Intraday Alerts

Alert Time
Up 2% about 5 hours ago
Lower Bollinger Band Support about 6 hours ago
Up 1% about 6 hours ago
2x Volume Pace about 11 hours ago
1.5x Volume Pace about 11 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Avacta Group Plc Description

Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.


Classification

Sector: Healthcare
Industry: Medical Devices
Keywords: Biotechnology Medicine Science Life Sciences Tools Branches Of Biology Medical Specialties Clinic Oncology Antibodies Immunology Disorders Immune System Assay Aptamer Synthetic Antibody

Is AVCT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 166.98
52 Week Low 47.325
Average Volume 2,723,376
200-Day Moving Average 108.30
50-Day Moving Average 78.18
20-Day Moving Average 52.83
10-Day Moving Average 51.14
Average True Range 3.96
RSI (14) 26.47
ADX 54.48
+DI 10.61
-DI 34.50
Chandelier Exit (Long, 3 ATRs) 66.86
Chandelier Exit (Short, 3 ATRs) 59.21
Upper Bollinger Bands 57.45
Lower Bollinger Band 48.21
Percent B (%b) 0.17
BandWidth 17.50
MACD Line -7.99
MACD Signal Line -9.32
MACD Histogram 1.3245
Fundamentals Value
Market Cap 143.42 Million
Num Shares 288 Million
EPS -0.16
Price-to-Earnings (P/E) Ratio -310.94
Price-to-Sales 18.17
Price-to-Book 12.68
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 53.76
Resistance 3 (R3) 53.40 51.70 53.09
Resistance 2 (R2) 51.70 50.68 51.88 52.87
Resistance 1 (R1) 50.73 50.05 51.21 51.09 52.65
Pivot Point 49.03 49.03 49.27 49.21 49.03
Support 1 (S1) 48.05 48.00 48.54 48.41 46.85
Support 2 (S2) 46.35 47.37 46.53 46.63
Support 3 (S3) 45.38 46.35 46.41
Support 4 (S4) 45.74